Balance sheetWarning
부채총계 급증 (+175%). 통계적 정황 신호이며 회계부정 단정이 아닙니다.
Immix Biopharma
IMMX · Nasdaq$13.91+0.58%
2026-09-04 closeImmix Biopharma last closed at $13.91 (+0.58%) on 2026-09-04. Listed on Nasdaq; price, financials and dividends update daily after market close.
Loading chart…
Close
Market Leader RS 99 · top 1%
New high + volume — the real recordrecord · not a prediction
Last 30 sessions
277 picks
Next-day win rate
44.2%
Avg next-day
-0.28%
vs market
-0.51%p
Every new-high-plus-volume pick we actually published (US market) — not this stock alone.
Signal history
| Date | Signal | +20 trading days |
|---|---|---|
A record, not a prediction.
How this is calculated
"·" means fewer than 20 trading days have passed since the event. Cup-and-handle entries are days our board actually showed the badge (archive grows daily since 2026-05-12); others are recomputed from price data.
Trade plan
Fill entry, stop, account size and risk percent to get a share count. The stop must sit below the entry.
A calculator · not advice or a guarantee
Financials & valuation at a glance
A
Overall: 건강관리 82/745 · top 11%
Factor composite · relative position in sector
PER — · PBR 54.75 — own-history percentile 100/100 · 0/100
Open self-history band
PER100/100
PBR0/100
Factual information · not investment advice
Past reported results · not investment advice
More — deeper indicators
Financial safety
Reference indicatorAs of 2024Distress zoneFinancial-metric reference signal
Altman Z'' zoneZ'' -12.57
Distress
Grey
Safe
- Altman Z''
- -12.57
- Beneish M-Score
- —
- Sloan accrual
- -30.58%
Statistical flag unavailable
부실·조작 위험을 나타내는 사실 지표입니다. 투자 조언이 아니며, 검증 전이라 참고용입니다.
Factual information, not investment advice.
Earnings quality · Piotroski F-Score
1/9Weak
Piotroski measures year-over-year financial improvement, not absolute quality.
Financial improvement score1/9
Profitability
- Positive ROANot passed
- Positive OCFNot passed
- Improving ΔROANot passed
- Accruals (OCF > net income)Pass
Leverage & liquidity
- Lower debtNot passed
- Higher current ratioNot passed
- No new sharesNot passed
Efficiency
- Higher gross marginNot passed
- Higher asset turnoverNot passed
Calculation note: F7(신주)은 equity/asset 유지로 근사
Already-stable companies may score lower when year-over-year improvement is limited.
Factual information, not investment advice.
Forensic signals
Anomaly and structural signals observed in the financial statements.
Factual information, not investment advice.
Connections
AI-extracted related companies · for reference
Competitors
AbbViePrice comovement r=0.17 (1 year)Bristol Myers SquibbPrice comovement r=0.10 (1 year)MerckPrice comovement r=0.15 (1 year)Boehringer IngelheimNovartisFate TherapeuticsPrice comovement r=0.21 (1 year)Kite PharmaAstraZenecaPfizerPrice comovement r=0.20 (1 year)Eli LillyPrice comovement r=0.16 (1 year)AmgenPrice comovement r=0.12 (1 year)Regeneron PharmaceuticalsPrice comovement r=0.18 (1 year)Johnson & JohnsonPrice comovement r=0.05 (1 year)
Same theme
BioNTech
Recent filings
Filings for overseas stocks are on the way. For now we cover Korean stocks only.
About Immix Biopharma
- What technical signals does Immix Biopharma (IMMX) have?
- Immix Biopharma current technical signals: no active technical signal.
- Is Immix Biopharma a cup-and-handle pattern?
- No. Immix Biopharma has no valid cup-and-handle signal right now.
- What are Immix Biopharma's financials and valuation?
- Immix Biopharma's income statement, balance sheet and cash flow are free for the most recent 8 years; the full history is on Pro. PER/PBR, dividend yield and sector valuation bands are free.
Like these rules? Backtest them.
Run this signal on this ticker in the free backtest builder — same window, no install.
Backtest this rule ↗Quantus Signal · live data · not investment advice · Privacy Policy